Covid-19 vaccine, Covaxin, being developed by Bharat Biotech has now reached phase-3 trials, Krishna Ella, Chairman and Managing Director, Bharat Biotech said on Monday.
Speaking virtually at a programme organised by the Indian School of Business, Ella informed that the company is also working on another vaccine for Covid-19 which will be in the form of nasal drops and can be ready by next year
“We partnered with ICMR for Covid-19 vaccine as we speak it entered the phase 3 trials,” he said.
Bharat Biotech is the only vaccine company in the world which has BSL3 production facility (Biosafety level 3), he said.
Last month the vaccine maker said it had successfully completed interim analysis of Phase I and II trials of the vaccine and is initiating Phase-III trials in 26,000 participants.
